The Power Of TAL: Genome Editing Techniques’ Coming Of Age
This article was originally published in Start Up
You may also be interested in...
The biotech looks to new targets -- HIV and monogenic diseases -- after a disappointing trial in diabetic neuropathy.
A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.